Drug intelligence / Profile preview

cyclophosphamide + docetaxel + doxorubicin + trastuzumab + zoledronic acid

Development stage: Unknown
Lead developer: Takeda
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This combination is used in the treatment of HER2-positive breast cancer. **Cyclophosphamide** and **doxorubicin** are chemotherapeutic agents that work by interfering with DNA replication and function. **Docetaxel** is a taxane that inhibits cell division. **Trastuzumab** is a monoclonal antibody targeting the HER2 receptor, used in HER2-positive cancers. **Zoledronic acid** is a bisphosphonate that inhibits bone resorption and is used to prevent skeletal-related events in cancer patients. The combination enhances anti-tumor activity and may improve outcomes in breast cancer by synergizing with chemotherapy and anti-HER2 therapy.

Other names: zoledronic acid + doxorubicin + cyclophosphamide + docetaxel + trastuzumabZoledronic Acid Neoadjuvant in HER2+ Breast Cancer

Targets

FDPS (Farnesyl pyrophosphate synthase)TOP2A (DNA topoisomerase II)ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on cyclophosphamide + docetaxel + doxorubicin + trastuzumab + zoledronic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + docetaxel + doxorubicin + trastuzumab + zoledronic acid.

Explore the full profile